In the OHSU-AML cohort, high expression of IGF2BP3 was associated with poor overall prognosis of AML (HR = 1.114, 95% CI = 1.006–1.233, P = 0.038), and HNRNPA2B1 expression was not associated with overall survival in patients with AML (P = 0.421). The gene discussed is IGF2BP3; the disease is acute myeloid leukemia.